Pharma and Healthcare: Q1FY26: Steady Revenues, Margins Under Pressure
he India Pharma and Healthcare sector is expected to see steady revenue growth. However, EBITDA margins are expected to show a decline for Q1FY26E
224 Views
Upgrading Korea to Overweight; MSCI ACWI and Emerging Market Breakouts
MSCI $ACWI and Emerging Market $EEM Breakouts; Upgrading Korea $EWY to Overweight; Downgrading Broad Europe, but staying Overweight Germany,...
673 Views
#161 India Insights: India Eyes Rare Earth Push; IndusInd's Prerequisites from RBI, Insulin Scale Up
India aims to localize rare earth magnet production for EV and tech sectors, Hinduja Group faces RBI conditions for Indusind Bank
524 Views
HSIE Results Daily: Amber Enterprises, Eris Lifesciences, Kalpataru Projects International
Amber Enterprises: Amber’s Q4FY25 revenue grew by 34% YoY to INR 37.54bn, mainly led by robust growth in consumer durables and electronics segments...
303 Views
APAC Healthcare Weekly (May 18)-Hengrui Medicine, Wuxi Biologics, Chugai, GC Biopharma, Mayne Pharma
Jiangsu Hengrui launches HK IPO. Wuxi Biologics to sell Germany plant. Chugai got Japan approval for gene therapy. Mayne Pharma was hit as FDA...
589 Views